{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:29:42Z","timestamp":1793755782450,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtct.2024.07.027","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T14:06:49Z","timestamp":1722953209000},"page":"1025.e1-1025.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-5980","authenticated-orcid":false,"given":"Albert","family":"Esquirol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jesus","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Ferr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3397-0202","authenticated-orcid":false,"given":"Beatriz","family":"Herruzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garcia-Cadenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Balaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-7410","authenticated-orcid":false,"given":"Sara","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hernandez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6741-971X","authenticated-orcid":false,"given":"Pedro","family":"Chorao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-0817","authenticated-orcid":false,"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-0356","authenticated-orcid":false,"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.07.027_bib0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using post-transplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/bmt.2014.62","article-title":"T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor","volume":"49","author":"Bashey","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0004","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0005","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","article-title":"Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors","volume":"20","author":"Di Stasi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0006","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.027_bib0007","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers a systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2024.07.027_bib0008","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0009","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0010","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose post-transplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.027_bib0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2)","key":"10.1016\/j.jtct.2024.07.027_bib0012","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignancies following a myeloablative conditioning: an update","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0013","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/bmt.2016.115","article-title":"Busulfan-based reduced-intensity conditioning regimens for haploidentical transplantation in relapsed\/refractory Hodgkin lymphoma: Spanish multicenter experience","volume":"51","author":"Gayoso","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0014","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/bmt.2017.111","article-title":"Single-agent GVHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies","volume":"52","author":"Esquirol","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41409-019-0771-2","article-title":"Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literatura","volume":"55","author":"Garc\u00eda-Cadenas I","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0016","doi-asserted-by":"crossref","first-page":"204.e1","DOI":"10.1016\/j.jtct.2022.01.020","article-title":"Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC","volume":"28","author":"Bail\u00e9n","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.07.027_bib0017","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41409-023-01980-y","article-title":"Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP\/EBMT","volume":"58","author":"Nagler","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0018","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.07.027_bib0019","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.07.027_bib0020","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2024.07.027_bib0021","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0022","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/bloodadvances.2020003779","article-title":"A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation","volume":"5","author":"Bejanyan","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.07.027_bib0023","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","article-title":"Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation","volume":"109","author":"Cutler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.027_bib0024","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.027_bib0025","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.027_bib0026","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.bbmt.2016.08.005","article-title":"Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free graft-versus-host disease prophylaxis for reduced-intensity conditioning umbilical cord blood transplantation","volume":"22","author":"Bejanyan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0027","doi-asserted-by":"crossref","unstructured":"Kharfan-Dabaja MA, Parody R, Perkins J, et al Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:438-444.","DOI":"10.1038\/bmt.2016.269"},{"key":"10.1016\/j.jtct.2024.07.027_bib0028","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3324\/haematol.2012.065599","article-title":"The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate","volume":"98","author":"Perez-Sim\u00f3n","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.07.027_bib0029","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/bmt.2016.163","article-title":"GVHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study","volume":"51","author":"Parody","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0030","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","article-title":"Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors","volume":"55","author":"Montoro","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0031","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.07.027_bib0032","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0033","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.027_bib0034","doi-asserted-by":"crossref","first-page":"614.e1","DOI":"10.1016\/j.jtct.2021.03.021","article-title":"Combining three different pretransplantation scores improves predictive value in patients after haploidentical stem cell transplantation with thiotepa, busulfan, and fludarabine conditioning and post-transplantation cyclophosphamide","volume":"27","author":"Esquirol","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.07.027_bib0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/bloodadvances.2023011814","article-title":"Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7\/8-matched unrelated donor","volume":"8","author":"Fingerson","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.07.027_bib0036","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","article-title":"Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation","volume":"25","author":"Dul\u00e9ry","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0037","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","article-title":"Thiotepa, fludarabine, and busulfan conditioning regimen before T cell replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients","volume":"25","author":"Pagliardini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101031","article-title":"Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: the Genova protocol","volume":"62","author":"Raiola","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2024.07.027_bib0039","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.07.027_bib0040","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.07.027_bib0041","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jha2.183","article-title":"Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis","volume":"2","author":"Hernani","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.jtct.2024.07.027_bib0042","doi-asserted-by":"crossref","first-page":"229.e1","DOI":"10.1016\/j.jtct.2023.11.010","article-title":"Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide","volume":"30","author":"Elmariah","year":"2024","journal-title":"Transplant Cell Ther"}],"updated-by":[{"DOI":"10.1016\/j.jtct.2025.06.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000}}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T18:04:41Z","timestamp":1759428281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724005578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666636724005578"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.027","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jtct.2025.06.011","asserted-by":"object"}]},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}